• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

    14.16 -0.56 (-3.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 644,532
    Open 14.60
    Bid (Size) 14.15 (100)
    Ask (Size) 14.16 (1,200)
    Prev. Close 14.72
    Today's Range 13.97 - 14.60
    52wk Range 5.280 - 26.95
    Shares Outstanding 74,681,872
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript ↗
    Soquelitinib advances across multiple indications, with cash runway extended into 2028. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Corvus Pharmaceuticals Q2 Earnings Call Highlights ↗
    Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +93.4%
    +93.4%
    1 Month
    +6.4%
    +6.4%
    3 Month
    +13.3%
    +13.3%
    6 Month
    -22.5%
    -22.5%
    1 Year
    +157.5%
    +157.5%

    More News

    Read More
    Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending Continues ↗
    Via Chartmill
    News headline image
    Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Corvus Pharmaceuticals Reports Q1 2026 Results; Atopic Dermatitis Program Takes Center Stage (NASDAQ:CRVS) ↗
    Via Chartmill
    Corvus Pharmaceuticals (NASDAQ:CRVS) Reports Q4 Earnings Miss Amid Positive Pipeline Data ↗
    Via Chartmill
    Topics Earnings
    Why Is CRVS Stock Rising Today? ↗
    Via Stocktwits
    News headline image
    Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Corvus (CRVS) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 ↗
    Via MarketBeat
    News headline image
    CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million ↗
    Via Stocktwits
    Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today ↗
    Via Stocktwits
    Topics Stocks
    News headline image
    Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? ↗
    Via Stocktwits
    News headline image
    Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data ↗
    Via The Motley Fool
    Topics Stocks
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise on Clinical Progress ↗
    Via Chartmill
    News headline image
    Corvus (CRVS) Q2 Loss Beats Estimates ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased ↗
    Via Stocktwits

    Frequently Asked Questions

    Is Corvus Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Corvus Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Corvus Pharmaceuticals, Inc. - Common Stock trade on?
    Corvus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Corvus Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Corvus Pharmaceuticals, Inc. - Common Stock is CRVS on the Nasdaq Stock Market
    What is the current price of Corvus Pharmaceuticals, Inc. - Common Stock?
    The current price of Corvus Pharmaceuticals, Inc. - Common Stock is 14.16
    When was Corvus Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Corvus Pharmaceuticals, Inc. - Common Stock was at 08/28/26 04:00 PM ET
    What is the market capitalization of Corvus Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Corvus Pharmaceuticals, Inc. - Common Stock is 1.06B
    How many shares of Corvus Pharmaceuticals, Inc. - Common Stock are outstanding?
    Corvus Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.